Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Restoration of intestinal barrier function by fexuprazan, a potassium-competitive acid blocker, in Caco-2 cells and its higher gastrointestinal distribution in rats
Publication Year: 2025 Source: Biomed Pharmacother PMID: 40412363
This study aimed to investigate the efficacy of fexuprazan in restoring intestinal barrier function in comparison with other potassium-competitive acid blockers (P-CABs) and esomeprazole. The effect of fexuprazan on trans-epithelial electrical resistance (TEER) value, mRNA and protein expression of tight junction genes, and cell morphology was investigated using a dextran …
Gamma-glutamyltransferase testing in paediatric inflammatory bowel disease to screen for primary sclerosing cholangitis: a diagnostic study based on routinely collected electronic healthcare data
Publication Year: 2025 Source: Arch Dis Child PMID: 40412823 DOI: 10.1136/archdischild-2024-327998
OBJECTIVE: To investigate, among children with inflammatory bowel disease (IBD) and elevated liver enzymes, what threshold of gamma-glutamyltransferase (GGT) best distinguishes those with and without primary sclerosing cholangitis (PSC). METHOD: Delayed-type diagnostic study with a paired design. Children with IBD were regularly screened with GGT (index test). Confirmation of PSC …
Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing
Publication Year: 2025 Source: Dermatol Ther (Heidelb) PMID: 40413675 DOI: 10.1007/s13555-025-01438-7
INTRODUCTION: Hidradenitis suppurativa (HS) is associated with inflammatory bowel disease (IBD). Using healthcare databases, an estimated 2.1% of patients with HS have IBD. Prospective screening of patients with HS with IBD sign/symptom-based questions and fecal calprotectin (FC) has not been studied. Our aim was to evaluate the prevalence of IBD …
Saikosaponin A ameliorates ulcerative colitis by targeting the CH25H/25-OHC axis to inhibit NLRP3 inflammasome in macrophages
Publication Year: 2025 Source: Phytomedicine PMID: 40414048
BACKGROUND: Ulcerative colitis (UC) has demonstrated an escalating global incidence and prevalence, thereby posing substantial challenges to public health. Despite recent advancements in therapeutic interventions, the clinical management of UC remains suboptimal, underscoring the urgent need for novel treatment strategies. Saikosaponin A (SSa), a bioactive compound derived from the traditional …
Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes
Publication Year: 2025 Source: Gastroenterol Hepatol PMID: 40414284 DOI: 10.1016/j.gastrohep.2025.502472
BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) features diverse clinical presentations and progressions, impacting IFX exposure. Understanding IFX serum concentration changes is crucial for tailored monitoring in specific patient groups. The main objective of this study was to analyze ITL trajectories in patients with IBD to identify distinct groups and …
Recombinant adeno-associated virus 2-mediated miRNA-199 suppression vector alleviates dextran sulfate sodium-induced ulcerative colitis in mice
Publication Year: 2025 Source: Virus Res PMID: 40414306
AIM: Mouse colonic tissue was transfected with a recombinant adeno-associated virus (rAAV) 2 vector. We aimed to determine whether the rAAV vector could mediate gene expression in the colonic tissue and the role of microRNA (miRNA)-199a-5p in regulating the colonic inflammatory response in dextran sulfate sodium (DSS)-treated mice. METHODS: Different …
A series of Sickle cell disease-associated inflammatory bowel diseases: high prevalence of colonic involvement and primary sclerosing cholangitis
Publication Year: 2025 Source: Clin Res Hepatol Gastroenterol PMID: 40414421 DOI: 10.1016/j.clinre.2025.102615
OBJECTIVE: Co-occurrence of Sickle Cell Disease (SCD) and Inflammatory Bowel Diseases (IBD) has been scarcely reported. Our aim was to explore the intersection between SCD and IBD, focusing on the impact of SCD on the natural course of IBD and drug safety. METHODS: We conducted a multicenter retrospective case-control study …
Advanced combination therapy in inflammatory bowel disease
Publication Year: 2025 Source: Joint Bone Spine PMID: 40414524
No Abstract
Dual B-cell targeting in systemic lupus erythematosus: The role of combined and sequential therapy with rituximab and belimumab
Publication Year: 2025 Source: Autoimmun Rev PMID: 40414587
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by immune dysregulation and autoantibody production. Despite advances in treatment, achieving sustained disease control remains challenging. Rituximab (RTX) and belimumab (BELI) are two B-cell-targeting biologics with complementary mechanisms of action, leading to increasing interest in their combination as a therapeutic …
Therapeutic adherence in inflammatory bowel disease: User guide from a multidisciplinary modified Delphi consensus
Publication Year: 2025 Source: Dig Liver Dis PMID: 40414777 DOI: 10.1016/j.dld.2025.04.032
BACKGROUND: Therapeutic non-adherence can significantly impair the quality of life of patients affected by inflammatory bowel disease (IBD), leading to worse treatment outcomes, more frequent hospitalizations, and increased healthcare expenses. Identifying and enhancing treatment adherence is a key goal in managing IBD. AIM: To establish a consensus on the definition …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide